Queensland, Australia

Zee Upton

USPTO Granted Patents = 11 


 

Average Co-Inventor Count = 2.1

ph-index = 3

Forward Citations = 27(Granted Patents)


Location History:

  • Indooroopilly, AU (2010 - 2014)
  • Brisbane, AU (2014)
  • Queensland, AU (2009 - 2015)
  • Indooropilly, AU (2017)
  • Kenmore Hills, AU (2015 - 2018)

Company Filing History:


Years Active: 2009-2018

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Zee Upton: Innovator in Cell Modulation and Therapeutic Applications

Introduction

Zee Upton is a prominent inventor based in Queensland, Australia, known for his significant contributions to the field of cell modulation and therapeutic applications. With a total of 11 patents to his name, Upton has developed innovative methods and agents that have the potential to transform treatments for various hyperproliferative cell disorders.

Latest Patents

Upton's latest patents include groundbreaking inventions such as "Complex-formation-modulating agents and uses therefor." This invention discloses methods and agents for modulating the proliferation, migration, and survival of cells. The invention particularly focuses on molecules that inhibit the binding of vitronectin to its binding partners, which can lead to the inhibition of hyperproliferative cell activities. Another notable patent is "Vitronectin:keratinocyte growth factor chimeras," which provides isolated protein complexes that enable the activation of both keratinocyte growth factor receptors and integrin receptors for vitronectin. These complexes have promising applications in wound healing, tissue engineering, and cancer treatment, particularly in inhibiting cancer cell metastasis.

Career Highlights

Throughout his career, Zee Upton has worked with esteemed institutions such as Queensland University of Technology. His research has focused on developing innovative solutions that address critical health challenges, particularly in the realm of cancer and tissue regeneration.

Collaborations

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…